The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
Open accessAbstract
BACKGROUND: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum-free interval (PFI)] is unclear. PATIENTS AND METHODS: within OVA-301, we therefore now report on the outcomes for the 214 cases in this subgroup. RESULTS: Trabectedin/PLD resulted in a 35% risk reduction of disease progression (DP) or death [hazard ratio (HR) = 0.65, 95% confidence interval (CI), 0.45-0.92; P = 0.0152; median progression-free survival (PFS) 7.4 versus 5.5 months], and a significant 41% decrease in the risk of death (HR = 0.59; 95% CI, 0.43-0.82; P = 0.0015; median survival 23.0 versus 17.1 months). The safety of trabectedin/PLD in this subset mimicked that of the overall population. Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), although patients in the trabectedin/PLD arm had a slightly lower proportion of further platinum (49% versus 55%). Importantly, patients in the trabectedin/PLD arm survived significantly longer after subsequent platinum (HR = 0.63; P = 0.0357; median 13.3 versus 9.8 months). CONCLUSION: This hypothesis-generating analysis demonstrates that superior benefits with trabectedin/PLD in terms of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease (PFI 6-12 months).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Self-citation
Cited by
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Self-citationTreatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Treatment of recurrent ovarian cancer
Pignata, S., C Cecere, S., Du Bois, A., Harter, P., & Heitz, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx441 · Cited by 338
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Assessing the in Vivo Efficacy of Doxorubicin Loaded Hyaluronan Nanoparticles
El-Dakdouki, M. H., Xia, J., Zhu, D. C., Kavunja, H., Grieshaber, J., O’Reilly, S., McCormick, J. J., & Huang, X. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am404946v · Cited by 69
Metadata
- Authors
- Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., Lebedinsky, C., Parekh, T., Gómez, J., Park, Y. C., Alfaro, V., & Monk, B. J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 22
- Issue
- 1
- Pages
- 39-48
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2171318838
- Cited by
- 163
- References
- 1
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. https://app.cochat.ai/papers/10.1093/annonc/mdq352
- The paper
- Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., Lebedinsky, C., Parekh, T., Gómez, J., Park, Y. C., Alfaro, V., & Monk, B. J. (2011). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Annals of Oncology. https://doi.org/10.1093/annonc/mdq352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.